Treatment of High-Level Gentamicin-Resistant Enterococcus faecalis Endocarditis with Daptomycin plus Ceftaroline
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
A recurrent case of left-sided endocarditis caused by high-level aminoglycoside-resistant Enterococcus faecalis was successfully treated with ceftaroline and daptomycin. This combination demonstrated excellent synergy in vitro . Mechanistically, ceftaroline enhanced binding of daptomycin to the cell membrane and sensitized E. faecalis to killing by human cathelicidin LL-37, a cationic innate host defense peptide. Daptomycin plus ceftaroline may be considered in salvage therapy in E. faecalis endovascular infections and requires further study.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A number of in vitro evaluations [214][215][216] suggested that ampicillin and ceftaroline in combination with daptomycin demonstrate the greatest synergistic activity compared with other β-lactam-daptomycin combinations.”
Citations
Cites
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Dvorchik, B. H., Brazier, D., DeBruin, M. F., & Arbeit, R. D. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1318-1323.2003 · Cited by 358
Pogliano, J., Pogliano, N., & Silverman, J. A. (2012) · Journal of Bacteriology · doi:10.1128/jb.00011-12 · Cited by 319 · cited 2×
“Microscopy method details have been described elsewhere (2, 8).”
MethodSelf-citationPharmacokinetics of ceftriaxone in humans
Patel, I. H., Chen, S., Parsonnet, M., Hackman, M. R., Brooks, M. A., Konikoff, J., & Kaplan, S. A. (1981) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.20.5.634 · Cited by 244
Gavaldà, J., Len, O., Miró, J. M., Muñoz, P., Montejo, M., Alarcón, A., de la Torre-Cisneros, J., Peña, C., Martínez-Lacasa, X., Sarria, C., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-8-200704170-00008 · Cited by 202 · cited 1×
“We point out that the ceftriaxone dose utilized initially was lower than that recommended in the literature and may have led to treatment failure (9).”
BackgroundSakoulas, G., Bayer, A. S., Pogliano, J., Tsuji, B. T., Yang, S.-J., Mishra, N. N., Nizet, V., Yeaman, M. R., & Moise, P. A. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05551-11 · Cited by 176 · cited 3×
“Microscopy method details have been described elsewhere (2, 8).”
BackgroundMethodSelf-citationPharmacokinetics of Sulbactam/Ampicillin in Humans: A Review
Foulds, G. (1986) · Clinical Infectious Diseases · doi:10.1093/clinids/8.supplement_5.503 · Cited by 137
Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci
Rand, K. H. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh104 · Cited by 112
Rose, W. E., Schulz, L. T., Andes, D., Striker, R., Berti, A. D., Hutson, P. R., & Shukla, S. K. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00797-12 · Cited by 111 · cited 2×
“faecalis and Enterococcus faecium, and a published report of synergy between daptomycin and ceftaroline against MRSA (3), ampicillin was discontinued and ceftaroline at 600 mg i.”
Background
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent
Ridyard, K. E., & Overhage, J. (2021) · Antibiotics · doi:10.3390/antibiotics10060650 · Cited by 270
“The combination has also been shown to sensitize Enterococcus faecalis to LL-37 [210].”
BackgroundA Current Perspective on Daptomycin for the Clinical Microbiologist
Humphries, R. M., Pollett, S., & Sakoulas, G. (2013) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-13 · Cited by 240
Self-citationBeganovic, M., Luther, M. K., Rice, L. B., Arias, C. A., Rybak, M. J., & LaPlante, K. L. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy064 · Cited by 234
“faecalis infections have been published [24, 26].”
BackgroundInfluentialMechanisms of drug resistance: daptomycin resistance
Tran, T. T., Munita, J. M., & Arias, C. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12948 · Cited by 234
Whole-Genome Analyses of Enterococcus faecium Isolates with Diverse Daptomycin MICs
Diaz, L., Tran, T. T., Munita, J. M., Miller, W. R., Rincon, S., Carvajal, L. P., Wollam, A., Reyes, J., Panesso, D., Rojas, N. L., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02686-14 · Cited by 139
Smith, J. R., Barber, K. E., Raut, A., Aboutaleb, M., Sakoulas, G., & Rybak, M. J. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv007 · Cited by 148
Self-citationTornero, E., Senneville, É., Euba, G., Petersdorf, S., Rodríguez-Pardo, D., Lakatos, B. K., Ferrari, M. C., Pilares, M., Bahamonde, A., Trebše, R., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12721 · Cited by 102
“Other potential combinations for the future could be a b-lactam plus daptomycin [22,23] or fosfomycin [24].”
BackgroundSakoulas, G., Rose, W., Nonejuie, P., Olson, J., Pogliano, J., Humphries, R., & Nizet, V. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02274-13 · Cited by 94
“faecalis aortic valve endocarditis (24).”
Self-citationYim, J., Smith, J. R., & Rybak, M. J. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1922 · Cited by 100
Dhand, A., & Sakoulas, G. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.09.005 · Cited by 80
Self-citationTreatment of Enterococcus faecalis Infective Endocarditis: A Continuing Challenge
Hidalgo, L. H., Fernández-Rubio, B., Márquez, R. L., López-Cortés, L. E., Gil-Navarro, M. V., & de Alarcón, A. (2023) · Antibiotics · doi:10.3390/antibiotics12040704 · Cited by 81
Renzoni, A., Kelley, W. L., Rosato, R. R., Martínez, M. P. S., Roch, M., Fatouraei, M., Haeusser, D. P., Margolin, W., Fenn, S. J., Turner, R. D., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01634-16 · Cited by 66
“Interestingly, in enterococci the ability of several -lactams, especially ampicillin (AMP), ceftaroline (CPT), and ertapenem (ERT), to provide synergistic activity with DAP and prevent the emergence of DAP nonsusceptibility has also been demonstrated (43, 44).”
BackgroundSmith, J. R., Barber, K. E., Raut, A., & Rybak, M. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00053-15 · Cited by 62
“AMP is frequently employed in combination therapy for enterococcal infections, and CPT has been demonstrated to provide synergistic activity with DAP in clinical cases (6, 26).”
BackgroundBacterial cell membranes and their role in daptomycin resistance: A review
Nguyen, A. H., Hood, K. S., Mileykovskaya, E., Miller, W. R., & Tran, T. T. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1035574 · Cited by 66
“disrupt cell wall biosynthesis is also supported by multiple in vitro and ex vivo studies where synergy or re-sensitization of DAP was observed upon combination with cell-wall acting antibiotics such as β-lactams (Dhand et al., 2011; Sakoulas et al., 2013; Sakoulas et al., 2014; Smith et al., 2015a; Smith et al., 2015…”
BackgroundEnterococcal Endocarditis Revisited
Pericàs, J. M., Zboromyrska, Y., Cervera, C., Castañeda, X., Almela, M., García-de-la-Mària, C., Mestres, C. A., Falces, C., Quintana, E., Ninot, S. P. I., et al. (2015) · Future Microbiology · doi:10.2217/fmb.15.46 · Cited by 60
What’s New in the Treatment of Enterococcal Endocarditis?
Nigo, M., Munita, J. M., Arias, C. A., & Murray, B. E. (2014) · Current Infectious Disease Reports · doi:10.1007/s11908-014-0431-z · Cited by 59
Kebriaei, R., Rice, S., Singh, K. V., Stamper, K. C., Dinh, A. Q., Ríos, R., Díaz, L., Murray, B. E., Munita, J. M., Tran, T. T., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00315-18 · Cited by 45
Hindler, J. A., Wong‐Beringer, A., Charlton, C. L., Miller, S. A., Kelesidis, T., Carvalho, M., Sakoulas, G., Nonejuie, P., Pogliano, J., Nizet, V., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05077-14 · Cited by 44
Self-citationTreatment of gram - positive infections in critically ill patients
Guillamet, C. V., & Kollef, M. H. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-92 · Cited by 55
“However, a number of case series have recently appeared suggesting that ceftaroline alone, or in combination with another agent, can be used to treat such infections attributed to MRSA or Enterococcus faecalis [79-83].”
BackgroundBartash, R. M., & Nori, P. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2017.07.019 · Cited by 49
Benamu, E., & Deresinski, S. C. (2018) · F1000Research · doi:10.12688/f1000research.11831.1 · Cited by 44
“Combined with ceftaroline at a dose of 600 mg every eight hours, daptomycin (at 8 mg/kg dosing) was successfully used to treat a 63-year-old man with E. faecalis endocarditis unresponsive to other therapies 172 .”
MethodSnyder, A. D. H., Werth, B. J., Nonejuie, P., McRoberts, J. P., Pogliano, J., Sakoulas, G., Yim, J., Singh, N. B., & Rybak, M. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00687-16 · Cited by 41
“Fosfomycin exposure appeared to reduce cell surface charge, which suggests that the mechanism of synergy is similar to that seen with beta-lactams and daptomycin against enterococci and Staphylococcus aureus (27, 44, 45).”
ResultSelf-citationTherapeutic options for vancomycin-resistant enterococcal bacteremia
Barber, K. E., King, S. T., Stover, K. R., & Pogue, J. M. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1001839 · Cited by 39
Smith, J. R., Yim, J., Raut, A., & Rybak, M. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03006-15 · Cited by 35
Jahanbakhsh, S., Singh, N. B., Yim, J., Kebriaei, R., Smith, J. R., Lev, K. L., Tran, T. T., Rose, W. E., Arias, C. A., & Rybak, M. J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02074-19 · Cited by 35
Chuang, Y., Chen, P., Lin, C., Chen, Y., Wang, J., & Chang, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-19986-8 · Cited by 31
Stryjewski, M. E., Jones, R. N., & Corey, G. R. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.11.016 · Cited by 23
“Sakoulas et al. described a patient with left-sided IE due to Enterococcus faecalis with high-level gentamicin resistance (Sakoulas et al., 2013).”
BackgroundCarreno, J. J., Kenney, R. M., Divine, G., Vázquez, J. A., & Davis, S. L. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016673858 · Cited by 25
Chuang, Y., Wang, J., Yang, J.-L., Lin, C., Huang, S., Chen, Y., & Chang, S. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.10.017 · Cited by 22
Combination antibiotic therapy for the treatment of infective endocarditis due to enterococci
Leone, S., Noviello, S., & Esposito, S. (2015) · Infection · doi:10.1007/s15010-015-0836-0 · Cited by 22
Growth Arrest of Staphylococcus aureus Induces Daptomycin Tolerance via Cell Wall Remodelling
Ledger, E. V. K., & Edwards, A. M. (2023) · mBio · doi:10.1128/mbio.03558-22 · Cited by 21
Left-sided infective endocarditis in patients with liver cirrhosis
Ruiz‐Morales, J., Georgieva, R. I., Fernández‐Hidalgo, N., García-Cabrera, E., Miró, J. M., Muñóz, P., Almirante, B., Plata, A., Ramallo, V. J. G., Gálvez-Acebal, J., et al. (2015) · Journal of Infection · doi:10.1016/j.jinf.2015.09.005 · Cited by 20
Pericàs, J. M., García-de-la-Mària, C., Brunet, M., Armero, Y., García-González, J. A., Casals, G., Almela, M., Quintana, E., Falces, C., Ninot, S. P. I., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx016 · Cited by 21
Lennard, P. R., Hiemstra, P. S., & Nibbering, P. H. (2023) · Antibiotics · doi:10.3390/antibiotics12101518 · Cited by 16
Matono, T., Hayakawa, K., Hirai, R., Tanimura, A., Yamamoto, K., Fujiya, Y., Mawatari, M., Kutsuna, S., Takeshita, N., Mezaki, K., et al. (2016) · BMC Research Notes · doi:10.1186/s13104-016-2003-9 · Cited by 16
Therapeutic Options for Infections Due to vanB Genotype Vancomycin-Resistant Enterococci
Riccardi, N., Monticelli, J., Antonello, R. M., Lallo, G. D., Frezza, D., Luzzati, R., & Bella, S. D. (2020) · Microbial Drug Resistance · doi:10.1089/mdr.2020.0171 · Cited by 19
“42 Of note, daptomycin is not indicated in respiratory infections due to inactivation by the surfactant.”
Labibzadeh, M., Kaydani, G. A., Savari, M., & Ekrami, A. (2018) · Polish Journal of Microbiology · doi:10.21307/pjm-2018-043 · Cited by 21
“faecalis of HLGR phenotype was demonstrated after administration of daptomycin plus ceftaroline (Sakoulas et al. 2013b).”
BackgroundSupandy, A., Mehta, H. H., Tran, T. T., Miller, W. R., Zhang, R., Xu, L., Arias, C. A., & Shamoo, Y. E. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02333-21 · Cited by 15
The combination of ampicillin plus ceftaroline is synergistic againstEnterococcus faecalis
Werth, B. J., & Abbott, A. N. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv125 · Cited by 16
Werth, B. J., & Shireman, L. M. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02235-16 · Cited by 16
Ingram, P. R., Ng, J., Mathieson, C., Mowlaboccus, S., Coombs, G. W., Raby, E., & Dyer, J. R. (2021) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlab128 · Cited by 13
Piszczek, J., Hutchinson, J., & Partlow, E. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku381 · Cited by 8
New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended
Oliva, A., Dezza, F. C., Cancelli, F., Curtolo, A., Falletta, A., Volpicelli, L., & Venditti, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247693 · Cited by 7
Ceftaroline—An Anti-MRSA Cephalosporin and Its Implications for Singapore
Chen, H. H., Hon, P. Y., & Hsu, L. Y. (2014) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.v43n3p177 · Cited by 7
Adema, J. L., Ahiskali, A., Fida, M., Hornback, K. M., Stevens, R. W., & Rivera, C. G. (2023) · Pathogens · doi:10.3390/pathogens12050703 · Cited by 6
“[73] Patient case of enterococcal IE treatment failure to 3 regimens prior to switching to CPT/DAP Clearance of blood cultures observed upon switch to CPT/DAP CPT/DAP can be considered as rescue therapy for blood culture clearance in IE secondary to E.”
BackgroundMethodInfluentialCăliman-Sturdza, O. A. (2024) · Infectious diseases · doi:10.5772/intechopen.114918 · Cited by 5
Enterococcal Infections in Adults
Reyes, K., Zervos, M., & John, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-47266-9_3 · Cited by 5
Ramin, B., Asadpour, L., Tehrani, H. F., & Amirmozafari, N. (2018) · Modern Medical Laboratory Journal · doi:10.30699/mmlj17.1.2.68 · Cited by 4
“They have been then detected with increasing frequency in specimens from hospitalized patients, and in the intestinal tract of humans and animals (7).”
BackgroundPincus, N. B., Joshi, T., Gatesy, S. W. M., Al-Heeti, O., Moore, W. J., & Bachta, K. E. R. (2022) · IDCases · doi:10.1016/j.idcr.2022.e01593 · Cited by 4
Ceftaroline Plus Ampicillin Against Gram-Positive Organisms: Results from E-Test Synergy Assays
D’Arezzo, S., Mazzarelli, A., Venditti, C. C., Nisii, C., Petrosillo, N., Giuli, C. D., Vulcano, A., Paglia, M. G., Bordi, E., Di, A., et al. (2016) · Microbial Drug Resistance · doi:10.1089/mdr.2016.0030 · Cited by 3
“16,23 Recently, the time-kill assay was used to demonstrate that the combination of ampicillin and ceftaroline is synergistic against E. faecalis (the authors did not include E. faecium in their study) and is more active in vitro than ampicillin plus ceftriaxone.”
Daptomycin and Ampicillin Combination for Treatment of Enterococcus faecalis Endocarditis
Sierra‐Hoffman, M., Iznaola, O., Lamp, K. C., Mohr, J., & Winn, R. E. (2015) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000000282 · Cited by 3
“ceftaroline in addition to surgery.(20) Combinations of daptomycin and ampicillin in vitro have demonstrated a delayed ability to select out for strains of Enterococcus with minimum inhibitory concentrations (MICs) greater than 4mg/L after multiple serial passages.”
BackgroundEnterococcus - Unveiling the Emergence of a Potent Pathogen
Téllez‐Isaías, G., Graham, D. L., & El-Ashram, S. A. (2024) · Infectious diseases · doi:10.5772/intechopen.114606 · Cited by 2
Cañas, M.-A., García‐González, J., Luque-Paz, D., Cuervo, G., Krivak, F., Nin-Blanch, J., Meneses, M. H., Falces, C., Maristany, M., Perissinotti, A., et al. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag136 · Cited by 2
Cave, K., & Gould, I. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00138-9 · Cited by 2
Heterogeneous collateral effects in daptomycin-resistant E. faecalisPreprint
Huynh, A., Maltas, J., & Wood, K. B. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.07.570714 · Cited by 3
“A similar “seesaw" effect has also been observed in E. fae-92 calis ( Sakoulas et al., 2013 ; Jahanbakhsh et al., 2020 ; Maltas and Wood, 2019 ), and recent work has linked CRO hypersensitivity to DAP-driven mutations in the LiaSFR system ( Khan, 2020 ; Khan et al., 2019b ).”
BackgroundKrishnan, A., Rajakumar, I., & Salmon, J. (2025) · Journal of the Association of Medical Microbiology and Infectious Disease Canada · doi:10.3138/jammi-2023-0038 · Cited by 1
Shah, S., Bandali, A., Pontiggia, L., & Bias, T. E. (2020) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000000837 · Cited by 1
“In addition, mutations in liaFSR and yycFGHIJ are involved in changes in cellwall homeostasis and stress response.(20,22,23) Controversy still lies in appropriate dosing schemes based on proposed breakpoints and achievement of clinical success.”
BackgroundIs an Aminoglycoside Still Required for the Treatment of Enterococcal Endocarditis?
Levine, D. P. (2013) · Current Infectious Disease Reports · doi:10.1007/s11908-013-0355-z
Advances in the Diagnosis and Treatment of Infective Endocarditis
Turner, R. B., & Schwartz, J. (2017) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-5225-2092-4.ch010
Smith, J. R., Claeys, K. C., Zasowski, E. J., Yim, J., & Rybak, M. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-46718-4_21
Jones, R. N. (2015) · Cambridge University Press eBooks · doi:10.1017/cbo9781139855952.154
Combined Antimicrobial Therapy for Infective Endocarditis
Gomez-Villegas, S. I., Miller, W. R., & Arias, C. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-65839-6_16
Stoorvogel, H. H., Hulscher, M., Kolwijck, E., Veld, R. A. G. H. I. ’., Zeren, A., Schouten, J. A., ten Oever, J., & Wertheim, H. F. L. (2025) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-025-05339-7
Foster, R. A., Cluck, D. B., Rogers, D. J., White, B. P., Daut, L., Bland, C. M., Webb, B. J., Henao‐Martínez, A. F., & Chastain, D. B. (2026) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361261499816
Metadata
- Authors
- Sakoulas, G., Nonejuie, P., Nizet, V., Pogliano, J., Crum-Cianflone, N., & Haddad, F.
- Affiliations
- University of California San Diego (US)
- Division of Infectious Diseases, Naval Medical Center San Diego, San Diego, California, USA
- Sharp Grossmont Hospital (US)
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2013-08
- Volume
- 57
- Issue
- 8
- Pages
- 4042-4045
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3719745
- OpenAlex
- W2030076485
- Semantic Scholar
- 83393aebf3bb4fa317d96fadf422d5cf2d77fa01
- Cited by
- 65
- References
- 9
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 6 · 2022: 4 · 2021: 4 · 2020: 3 · 2018: 6 · 2017: 7 · 2016: 6 · 2015: 12 · 2014: 8 · 2013: 3
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Forest Laboratories
- Pfizer Pharmaceuticals
- National Institute of Allergy and Infectious Diseases (U54AI057153, R01AI052453, R37AI052453)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD071600)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Keywords
- Enterococcus faecalis, infective endocarditis, daptomycin, ceftaroline, aminoglycoside resistance, gentamicin resistance, antibiotic synergy, cathelicidin LL-37, antimicrobial peptides, salvage therapy, endovascular infection, left-sided endocarditis
- MeSH terms
- Ceftaroline, Anti-Bacterial Agents, Cell Membrane, Cephalosporins, Drug Synergism, Endocarditis, Bacterial, Gentamicins, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Enterococcus faecalis, Daptomycin, Antimicrobial Cationic Peptides, Drug Resistance, Bacterial, Cathelicidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.